Sigurd Broesby-Olsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sigurd Broesby-Olsen has a total of 265 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Bindslev-Jensen
Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital Odense Denmark
11 shared publications - Charlotte Gotthard Mortz
Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA) Odense University Hospital Odense Denmark
9 shared publications - Michael B. Møller
Odense University Hospital, Odense, Denmark
8 shared publications Hanne Vestergaard
Department of Hematology, Odense University Hospital, Odense, Denmark
6 shared publications- Knut Brockow
Department of Dermatology and Allergy Biederstein, School of Medicine and Health Technical University of Munich Munich Germany
5 shared publications - Thomas Kristensen
Department of Pathology, Odense University Hospital, Odense, Denmark
4 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (11)
Elevated Risk of Psychotropic Drug Prescriptions in Adults With Mastocytosis: A Danish Matched Cohort Study
Background: Mastocytosis is a clonal mast cell disorder characterized by chronic mediator‐related symptoms and heterogeneous systemic involvement. Neuropsychiatric symptoms are frequently reported, yet population‐based evidence on incident depression and/or anxiety remains limited. Objective: To examine the mental health burden among patients with mastocytosis. Methods: We conducted a population‐based matched cohort study using Danish health registers to evaluate incident, pharmacologically treated depression/anxiety among adult patients diagnosed with mastocytosis between 2005 and 2023. Patients were matched 1:5 with individuals from the general Danish population on age, sex, Charlson Comorbidity Index, and educational level. Individuals with psychotropic drug (PD) prescription within 10 years prior to index were excluded. Cumulative risks were estimated using the Aalen‐Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazard regression. Results: We included 874 patients with mastocytosis and 4370 comparators. Patients had a higher risk of incident PD prescription in the 10 years following diagnosis ( p < 0.001). The 5‐year cumulative risk was 13.1% in patients and 8.4% in comparators. The HR for incident PD use was 1.72 (95% confidence interval 1.38–2.15, p < 0.001). Results were consistent across sensitivity and landmark analyses. Higher age, comorbidity, and shorter education were associated with increased risk. Conclusion: Mastocytosis was associated with an increased risk of PD prescriptions, possibly reflecting an increased burden of pharmacologically treated depression and/or anxiety, implying the importance of mental health awareness in clinical management.
- 15 November 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (11)
Open AccessElevated Risk of Psychotropic Drug Prescriptions in Adults With Mastocytosis: A Danish Matched Cohort Study
Background: Mastocytosis is a clonal mast cell disorder characterized by chronic mediator‐related symptoms and heterogeneous systemic involvement. Neuropsychiatric symptoms are frequently reported, yet population‐based evidence on incident depression and/or anxiety remains limited. Objective: To examine the mental health burden among patients with mastocytosis. Methods: We conducted a population‐based matched cohort study using Danish health registers to evaluate incident, pharmacologically treated depression/anxiety among adult patients diagnosed with mastocytosis between 2005 and 2023. Patients were matched 1:5 with individuals from the general Danish population on age, sex, Charlson Comorbidity Index, and educational level. Individuals with psychotropic drug (PD) prescription within 10 years prior to index were excluded. Cumulative risks were estimated using the Aalen‐Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazard regression. Results: We included 874 patients with mastocytosis and 4370 comparators. Patients had a higher risk of incident PD prescription in the 10 years following diagnosis ( p < 0.001). The 5‐year cumulative risk was 13.1% in patients and 8.4% in comparators. The HR for incident PD use was 1.72 (95% confidence interval 1.38–2.15, p < 0.001). Results were consistent across sensitivity and landmark analyses. Higher age, comorbidity, and shorter education were associated with increased risk. Conclusion: Mastocytosis was associated with an increased risk of PD prescriptions, possibly reflecting an increased burden of pharmacologically treated depression and/or anxiety, implying the importance of mental health awareness in clinical management.
- Open Access
- 29 January 2026
- Published by Wiley
Definition of standards for allergology specialty/subspecialty training in mast cell disorders, in Europe: a EAACI position paper
Mast cell disorders (MCD), including mastocytosis and mast cell (MC) activation syndrome (MCAS), encompass a heterogeneous spectrum of diseases often presenting with debilitating manifestations. Variable clinical manifestations, ranging from otherwise asymptomatic cutaneous forms to recurrent anaphylaxis, pose significant challenges for timely diagnosis and effective management. Despite increasing recognition of MCD in Europe, diagnosis is frequently delayed, and therapeutic approaches remain inconsistent, potentially due to gaps and disparities in training. An European Academy of Allergy and Clinical Immunology (EAACI) Task Force (TF) was created to address this need. Through iterative consensus, the TF members formulated ten expert-based recommendations outlining the minimum competencies that allergology and clinical immunology trainees should acquire regarding MCD. These include fundamental knowledge of MC biology, pathogenesis of clonality, recognition of systemic manifestations, diagnostic methodologies, pharmacological and preventive strategies, management of comorbid Hymenoptera venom allergy, pediatric aspects, communication skills, and how to acquire and consolidate expertise. This position paper underscores the need for harmonized competency-based training standards on MCD for Allergists and Clinical Immunologists across Europe. We advocate for the incorporation of these recommendations into national postgraduate curricula, aiming to foster earlier recognition, improve management, and ultimately enhance long-term outcomes for MCD patients.
- 29 January 2026
- Published by Wiley
Open AccessDefinition of standards for allergology specialty/subspecialty training in mast cell disorders, in Europe: a EAACI position paper
Mast cell disorders (MCD), including mastocytosis and mast cell (MC) activation syndrome (MCAS), encompass a heterogeneous spectrum of diseases often presenting with debilitating manifestations. Variable clinical manifestations, ranging from otherwise asymptomatic cutaneous forms to recurrent anaphylaxis, pose significant challenges for timely diagnosis and effective management. Despite increasing recognition of MCD in Europe, diagnosis is frequently delayed, and therapeutic approaches remain inconsistent, potentially due to gaps and disparities in training. An European Academy of Allergy and Clinical Immunology (EAACI) Task Force (TF) was created to address this need. Through iterative consensus, the TF members formulated ten expert-based recommendations outlining the minimum competencies that allergology and clinical immunology trainees should acquire regarding MCD. These include fundamental knowledge of MC biology, pathogenesis of clonality, recognition of systemic manifestations, diagnostic methodologies, pharmacological and preventive strategies, management of comorbid Hymenoptera venom allergy, pediatric aspects, communication skills, and how to acquire and consolidate expertise. This position paper underscores the need for harmonized competency-based training standards on MCD for Allergists and Clinical Immunologists across Europe. We advocate for the incorporation of these recommendations into national postgraduate curricula, aiming to foster earlier recognition, improve management, and ultimately enhance long-term outcomes for MCD patients.
- Open Access
- 29 May 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (11) , 1371
Reply to Urbina, F.; Benavides, A. Telangiectatic Mastocytosis: If It Is Not Mastocytosis, What Is It? Comment on “Brockow et al. Challenges in the Diagnosis of Cutaneous Mastocytosis. Diagnostics 2024, 14, 161”
We appreciate the interest and reflections of Urbina and Benavides on our recent article published in Diagnostics and presentation of their two new patients
- 29 May 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (11) , 1371
Open AccessReply to Urbina, F.; Benavides, A. Telangiectatic Mastocytosis: If It Is Not Mastocytosis, What Is It? Comment on “Brockow et al. Challenges in the Diagnosis of Cutaneous Mastocytosis. Diagnostics 2024, 14, 161”
We appreciate the interest and reflections of Urbina and Benavides on our recent article published in Diagnostics and presentation of their two new patients
- Open Access
- 3 January 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (1) , 43-53
Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study
Introduction: Mastocytosis is a group of rare heterogeneous diseases with a prevalence previously found to be 10–23 per 100,000 persons. More awareness and improvements in the diagnostic methods in later years have led to more patients being diagnosed. Here, we set out to present the prevalence and incidence rate of mastocytosis among the adult Danish population. By merging data from the Danish National Patient Register, the Danish Pathology Register and the Danish Cancer Register we included all adult patients (≥ 18 years) diagnosed with mastocytosis in Denmark prior to 2022. A cohort of 1,594 patients with mastocytosis was identified. The prevalence of mastocytosis was 27.43 per 100,000 persons (95% confidence interval [CI]: 25.95–28.96) as of January 1, 2022, and the 25-year average incidence rate between 1997 and 2021 was 1.21 per 100,000 persons (95%CI: 1.02–1.40) with an increasing incidence rate since 2002. We found a higher prevalence of mastocytosis among adults in the Danish population than previously reported, and an increasing incidence rate during the last 20 years. Increased awareness of the disease and better diagnostic methods most likely contributed to this.
- 3 January 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (1) , 43-53
Open AccessPrevalence and incidence of mastocytosis in adults: a Danish nationwide register study
Introduction: Mastocytosis is a group of rare heterogeneous diseases with a prevalence previously found to be 10–23 per 100,000 persons. More awareness and improvements in the diagnostic methods in later years have led to more patients being diagnosed. Here, we set out to present the prevalence and incidence rate of mastocytosis among the adult Danish population. By merging data from the Danish National Patient Register, the Danish Pathology Register and the Danish Cancer Register we included all adult patients (≥ 18 years) diagnosed with mastocytosis in Denmark prior to 2022. A cohort of 1,594 patients with mastocytosis was identified. The prevalence of mastocytosis was 27.43 per 100,000 persons (95% confidence interval [CI]: 25.95–28.96) as of January 1, 2022, and the 25-year average incidence rate between 1997 and 2021 was 1.21 per 100,000 persons (95%CI: 1.02–1.40) with an increasing incidence rate since 2002. We found a higher prevalence of mastocytosis among adults in the Danish population than previously reported, and an increasing incidence rate during the last 20 years. Increased awareness of the disease and better diagnostic methods most likely contributed to this.
- Open Access
- 11 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (2) , 161
Challenges in the Diagnosis of Cutaneous Mastocytosis
Background: Mastocytosis is characterized by an accumulation of clonal mast cells (MCs) in tissues such as the skin. Skin lesions in mastocytosis may be clinically subtle or heterogeneous, and giving the correct diagnosis can be difficult. Methods: This study compiles personal experiences together with relevant literature, discussing possible obstacles encountered in diagnosing skin involvement in mastocytosis and cutaneous mastocytosis (CM). Results: The nomenclature of the term “CM” is ambiguous. The WHO classification defines CM as mastocytosis solely present in the skin. However, the term is also used as a morphological description, e.g., in maculopapular cutaneous mastocytosis (MPCM). This is often seen in systemic, as well as cutaneous, mastocytosis. Typical CM manifestations (MPCM), including mastocytoma or diffuse cutaneous mastocytosis (DCM), all share a positive Darier’s sign, and can thus be clinically recognized. Nevertheless, distinguishing monomorphic versus polymorphic MPCM may be challenging, even for experienced dermatologists. Less typical clinical presentations, such as MPCM with telangiectatic erythemas (formerly called telangiectasia macularis eruptiva perstans), confluent, nodular or xanthelasmoid variants may require a skin biopsy for histopathological confirmation. Because MC numbers in CM have a large overlap to those in healthy and inflamed skin, detailed histopathological criteria to diagnose mastocytosis in MPCM are needed and have been proposed. D816V KIT mutational analysis in tissue is helpful for confirming the diagnosis. Biomarkers allow the prediction of the course of CM into regression or evolution of the disease. Further diagnostic measures should screen for concomitant diseases, such as malignant melanoma, and for systemic involvement. Conclusions: Whereas in typical cases the diagnosis of CM may be uncomplicated, less typical manifestations may require specific investigations for making the diagnosis and predicting its course.
- 11 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (2) , 161
Open AccessChallenges in the Diagnosis of Cutaneous Mastocytosis
Background: Mastocytosis is characterized by an accumulation of clonal mast cells (MCs) in tissues such as the skin. Skin lesions in mastocytosis may be clinically subtle or heterogeneous, and giving the correct diagnosis can be difficult. Methods: This study compiles personal experiences together with relevant literature, discussing possible obstacles encountered in diagnosing skin involvement in mastocytosis and cutaneous mastocytosis (CM). Results: The nomenclature of the term “CM” is ambiguous. The WHO classification defines CM as mastocytosis solely present in the skin. However, the term is also used as a morphological description, e.g., in maculopapular cutaneous mastocytosis (MPCM). This is often seen in systemic, as well as cutaneous, mastocytosis. Typical CM manifestations (MPCM), including mastocytoma or diffuse cutaneous mastocytosis (DCM), all share a positive Darier’s sign, and can thus be clinically recognized. Nevertheless, distinguishing monomorphic versus polymorphic MPCM may be challenging, even for experienced dermatologists. Less typical clinical presentations, such as MPCM with telangiectatic erythemas (formerly called telangiectasia macularis eruptiva perstans), confluent, nodular or xanthelasmoid variants may require a skin biopsy for histopathological confirmation. Because MC numbers in CM have a large overlap to those in healthy and inflamed skin, detailed histopathological criteria to diagnose mastocytosis in MPCM are needed and have been proposed. D816V KIT mutational analysis in tissue is helpful for confirming the diagnosis. Biomarkers allow the prediction of the course of CM into regression or evolution of the disease. Further diagnostic measures should screen for concomitant diseases, such as malignant melanoma, and for systemic involvement. Conclusions: Whereas in typical cases the diagnosis of CM may be uncomplicated, less typical manifestations may require specific investigations for making the diagnosis and predicting its course.
- Open Access
- 21 January 2023
- Published by Wiley in Clinical and Translational Allergy
- Vol. 13 (1) , e12217
Fractionated vaccination with mRNA COVID‐19 vaccine is safe for patients with polyethylene glycol allergy
- 21 January 2023
- Published by Wiley in Clinical and Translational Allergy
- Vol. 13 (1) , e12217
Open AccessFractionated vaccination with mRNA COVID‐19 vaccine is safe for patients with polyethylene glycol allergy
- Open Access
- 29 April 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (8) , 1367-1375
Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis
Background: Cutaneous lesions of mastocytosis (CLM) are often subtle and may require biopsy. However, dermatohistopathological criteria for CLM remain undefined.Objectives: To establish criteria for CLM by validating histological and molecular parameters.Methods: In skin samples from Caucasian patients with CLM and controls (atopic dermatitis, chronic urticaria, pruritus, tissue from tumor safety margin excisions), mast cell (MC) numbers, size, shape, distribution, immunostainability with a large panel of markers, pigmentation and presence of KIT D816V mutation were analysed.Results: Forty‐seven CLM patients (32 maculopapular cutaneous mastocytosis (MPCM), 15 mastocytomas) and 36 controls were included. Mastocytomas were easily identified by densely packed cuboidal MCs. In MPCM, skin MC density in CD117 stains was higher in CLM patients than in controls (P < 0.0001) and values correlated closely (r = 0.65, P < 0.0001) to results in tryptase stains. The optimized upper dermis cut‐off number of 62 MC/mm2 had a sensitivity and specificity of 92% in both stainings, corresponding to approximately 12 MC/high power field (HPF). MC size was larger in MPCM than in controls (P = 0.01). Interstitial (= not perivascular or periadnexal) MCs and stronger basal pigmentation of the epidermis were indicative of MPCM (P < 0.0001 each) and clusters of >3 nucleated MC/HPF exclusively found in MCPM. Surface markers CD2, CD25 and CD30 stained T‐lymphocytes, but only negligibly CLM MC. The KIT D816V mutation in formalin fixed paraffin embedded (FFPE) skin was evaluable in 87.5% of MCPM patients and had both 100% sensitivity and specificity.Conclusions: MPCM can be predicted by major and minor criteria combined in a scoring model. Presence of D816V mutation in FFPE skin and MC density > 27/HPF are >95%‐specific major criteria for MPCM. MC densities 12/HPF, interstitial MC, clusters and basal pigmentation are minor criteria.
- 29 April 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (8) , 1367-1375
Open AccessValidation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis
Background: Cutaneous lesions of mastocytosis (CLM) are often subtle and may require biopsy. However, dermatohistopathological criteria for CLM remain undefined.Objectives: To establish criteria for CLM by validating histological and molecular parameters.Methods: In skin samples from Caucasian patients with CLM and controls (atopic dermatitis, chronic urticaria, pruritus, tissue from tumor safety margin excisions), mast cell (MC) numbers, size, shape, distribution, immunostainability with a large panel of markers, pigmentation and presence of KIT D816V mutation were analysed.Results: Forty‐seven CLM patients (32 maculopapular cutaneous mastocytosis (MPCM), 15 mastocytomas) and 36 controls were included. Mastocytomas were easily identified by densely packed cuboidal MCs. In MPCM, skin MC density in CD117 stains was higher in CLM patients than in controls (P < 0.0001) and values correlated closely (r = 0.65, P < 0.0001) to results in tryptase stains. The optimized upper dermis cut‐off number of 62 MC/mm2 had a sensitivity and specificity of 92% in both stainings, corresponding to approximately 12 MC/high power field (HPF). MC size was larger in MPCM than in controls (P = 0.01). Interstitial (= not perivascular or periadnexal) MCs and stronger basal pigmentation of the epidermis were indicative of MPCM (P < 0.0001 each) and clusters of >3 nucleated MC/HPF exclusively found in MCPM. Surface markers CD2, CD25 and CD30 stained T‐lymphocytes, but only negligibly CLM MC. The KIT D816V mutation in formalin fixed paraffin embedded (FFPE) skin was evaluable in 87.5% of MCPM patients and had both 100% sensitivity and specificity.Conclusions: MPCM can be predicted by major and minor criteria combined in a scoring model. Presence of D816V mutation in FFPE skin and MC density > 27/HPF are >95%‐specific major criteria for MPCM. MC densities 12/HPF, interstitial MC, clusters and basal pigmentation are minor criteria.
- Open Access
Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence
Clinical validation of a new commercial highly sensitive KIT D816V mutation analysis in mastocytosis
Atopic diseases and type I sensitization from adolescence to adulthood in an unselected population (TOACS) with focus on predictors for allergic rhinitis
Background While much is known on childhood atopic diseases, knowledge about persistence of atopic diseases from childhood to adulthood is limited. We therefore aimed to study the clinical course of atopic diseases and Type I sensitization prospectively in an unselected cohort of adolescents followed into adulthood. Methods A cohort of unselected 8th grade school children (mean age 14 years) established in 1995 and followed‐up in 2010 were evaluated with questionnaire, clinical examination, skin prick tests and measurements of specific IgE. Results The lifetime prevalence of atopic diseases was high and increased significantly from adolescence (31%) to adulthood (57%); particularly allergic rhinitis increased with an incidence rate of 17.5/1000 person‐years. Childhood predictors for adult allergic rhinitis were atopic dermatitis, asthma and asymptomatic sensitisation to pollen and house dust mite. Among those with asymptomatic sensitization in adolescence; 53‐78% developed allergic rhinitis in adulthood. Furthermore, Type I sensitisation increased significantly from adolescence to adulthood mostly due to increased sensitisation to pollen. Type I sensitisation was found mainly in those with allergic rhinitis. A high number of adults had oral allergy symptoms due to the high number of birch pollen allergic individuals. Conclusion Persistence of atopic diseases in adulthood is common and a high proportion of the adult population is sensitized giving a high prevalence of allergic rhinitis. Many with asymptomatic sensitization in adolescence will develop allergic rhinitis in adult life. Focus should be on prevention of atopic diseases and sensitization already in childhood.
Atopic diseases and type I sensitization from adolescence to adulthood in an unselected population (TOACS) with focus on predictors for allergic rhinitis
Background While much is known on childhood atopic diseases, knowledge about persistence of atopic diseases from childhood to adulthood is limited. We therefore aimed to study the clinical course of atopic diseases and Type I sensitization prospectively in an unselected cohort of adolescents followed into adulthood. Methods A cohort of unselected 8th grade school children (mean age 14 years) established in 1995 and followed‐up in 2010 were evaluated with questionnaire, clinical examination, skin prick tests and measurements of specific IgE. Results The lifetime prevalence of atopic diseases was high and increased significantly from adolescence (31%) to adulthood (57%); particularly allergic rhinitis increased with an incidence rate of 17.5/1000 person‐years. Childhood predictors for adult allergic rhinitis were atopic dermatitis, asthma and asymptomatic sensitisation to pollen and house dust mite. Among those with asymptomatic sensitization in adolescence; 53‐78% developed allergic rhinitis in adulthood. Furthermore, Type I sensitisation increased significantly from adolescence to adulthood mostly due to increased sensitisation to pollen. Type I sensitisation was found mainly in those with allergic rhinitis. A high number of adults had oral allergy symptoms due to the high number of birch pollen allergic individuals. Conclusion Persistence of atopic diseases in adulthood is common and a high proportion of the adult population is sensitized giving a high prevalence of allergic rhinitis. Many with asymptomatic sensitization in adolescence will develop allergic rhinitis in adult life. Focus should be on prevention of atopic diseases and sensitization already in childhood.